<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="68554"><DrugName>DTaP-Hib, Beijing Minhai Biotechnology</DrugName><DrugSynonyms><Name><Value>DTaP-Hib, Beijing Minhai Biotechnology</Value></Name><Name><Value>vaccine (diphtheria/tetanus/pertussis/hemophilus influenzae type b), Beijing Minhai Biotechnology</Value></Name><Name><Value>meilianjitai</Value></Name></DrugSynonyms><CompanyOriginator id="1056577">Beijing Minhai Biotechnology Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="68554" type="Drug"><TargetEntity id="763604" type="siDrug">CPS-CTB</TargetEntity></SourceEntity><SourceEntity id="1056577" type="Company"><TargetEntity id="5035526675" type="organizationId">Beijing Minhai Biotechnology Co Ltd</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"></TargetEntity><TargetEntity id="033" type="ICD9"></TargetEntity><TargetEntity id="10034738" type="MEDDRA"></TargetEntity><TargetEntity id="D014917" type="MeSH"></TargetEntity><TargetEntity id="1489" type="ORPHANET"></TargetEntity><TargetEntity id="-320620987" type="omicsDisease"></TargetEntity><TargetEntity id="2337" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"></TargetEntity><TargetEntity id="D013742" type="MeSH"></TargetEntity><TargetEntity id="3299" type="ORPHANET"></TargetEntity><TargetEntity id="-687302618" type="omicsDisease"></TargetEntity><TargetEntity id="816" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"></TargetEntity><TargetEntity id="10013023" type="MEDDRA"></TargetEntity><TargetEntity id="D004165" type="MeSH"></TargetEntity><TargetEntity id="1679" type="ORPHANET"></TargetEntity><TargetEntity id="-360770994" type="omicsDisease"></TargetEntity><TargetEntity id="3234" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bordetella pertussis infection - China - Oct-2014</FirstLaunched><FirstLaunched>Clostridium tetani infection - China - Oct-2014</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - China - Oct-2014</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - China - Oct-2014</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12372">Protein subunit vaccine</Action><Action id="12373">Polysaccharide subunit vaccine</Action><Action id="12378">Prophylactic vaccine</Action><Action id="12375">Toxoid vaccine</Action></ActionsSecondary><Technologies><Technology id="208">Protein conjugation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="207">Protein conjugated</Technology></Technologies><LastModificationDate>2014-10-29T09:57:51.000Z</LastModificationDate><ChangeDateLast>2017-08-09T00:00:00.000Z</ChangeDateLast><AddedDate>2010-10-13T06:31:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1056577"&gt;Beijing Minhai Biotechnology&lt;/ulink&gt; has developed   and launched meilianjitai, a diphtheria-tetanus-acellular pertussis-Haemophilus influenzae b (DTaP-Hib) combination vaccine, for the  prevention of Haemophilus influenzae infection, diphtheria, tetanus and  pertussis infection in children aged older than 3 months [&lt;ulink linkType="Reference" linkID="1604847"&gt;1604847&lt;/ulink&gt;].  In July 2012, this vaccine was approved in China by the SFDA [&lt;ulink linkType="Reference" linkID="1346040"&gt;1346040&lt;/ulink&gt;]; by October 2014, the vaccine had been launched in China [&lt;ulink linkType="Reference" linkID="1604844"&gt;1604844&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By April 2010, a randomized, two-stage, parallel controlled, single center trial had been conducted in pediatrics (n = 720) to evaluate the safety and immunogenicity of DTaP-Hib. Results demonstrated the non-inferiority of DTaP-Hib vaccine to the control vaccine. In the treatment group, seroconversion rates of anti-pertussis toxoid (PT), anti-filamentous hemagglutinin (FHA), anti-diphtheria toxoid (DT), anti-tetanus toxoid (TT) and anti-polyribosyl-ribitol-phosphate (PRP) were comparable to that of control group. After primary and booster vaccination, seroprotective levels of anti-DT (&gt;/= 0.1 IU/ml), anti-TT (&gt;/= 0.1 IU/ml) and anti-PRP (&gt;/= 0.1 microg/ml) were achieved by nearly all the subjects [&lt;ulink linkType="Reference" linkID="1137507"&gt;1137507&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By June 2013, the project had received funding from the Chinese government as part of the national 863 project [&lt;ulink linkType="Reference" linkID="1604847"&gt;1604847&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-24T00:00:00.000Z</StatusDate><Source id="1604844" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-24T00:00:00.000Z</StatusDate><Source id="1604844" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-24T00:00:00.000Z</StatusDate><Source id="1604844" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-24T00:00:00.000Z</StatusDate><Source id="1604844" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-15T00:00:00.000Z</StatusDate><Source id="1137507" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-15T00:00:00.000Z</StatusDate><Source id="1137507" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-15T00:00:00.000Z</StatusDate><Source id="1137507" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-15T00:00:00.000Z</StatusDate><Source id="1137507" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1346040" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1346040" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1346040" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1346040" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Patent Added</Reason><Description>Patent Added:  &lt;ulink url="utility.patent?i_patent_id=PA5711970" linkType="patent" linkID="PA5711970"&gt;CN-101081296&lt;/ulink&gt;</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="921279" number="CN-101081296" title="A preparing method of B-type haemophilus influenzae capsular polysaccharide and its combined vaccine"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Kangtai Biological Products Co Ltd" id="1071345"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>